当前位置: 首页 >> 检索结果
8222. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review.
The prevalence of irritable bowel syndrome (IBS) in the United States is between 7% and 16%, most common in women and young people, with annual direct costs estimated at more than $1 billion dollars in the United States. Traditionally, the diagnosis of IBS has been based on the positive identification of symptoms that correlate with several different syndromes associated with disorders such as IBS diarrhea, IBS constipation, functional diarrhea, functional constipation, chronic functional abdominal pain, or bloating. Several peripheral and central mechanisms initiate gastrointestinal motor and sensory dysfunctions leading to IBS symptoms. Those dysfunctions may require evaluation in patients whose symptoms do not respond to first-line treatments.
8224. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
作者: Franco Locatelli.;Gerhard Zugmaier.;Carmelo Rizzari.;Joan D Morris.;Bernd Gruhn.;Thomas Klingebiel.;Rosanna Parasole.;Christin Linderkamp.;Christian Flotho.;Arnaud Petit.;Concetta Micalizzi.;Noemi Mergen.;Abeera Mohammad.;William N Kormany.;Cornelia Eckert.;Anja Möricke.;Mary Sartor.;Ondrej Hrusak.;Christina Peters.;Vaskar Saha.;Luciana Vinti.;Arend von Stackelberg.
来源: JAMA. 2021年325卷9期843-854页
Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
8225. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
作者: Patrick A Brown.;Lingyun Ji.;Xinxin Xu.;Meenakshi Devidas.;Laura E Hogan.;Michael J Borowitz.;Elizabeth A Raetz.;Gerhard Zugmaier.;Elad Sharon.;Melanie B Bernhardt.;Stephanie A Terezakis.;Lia Gore.;James A Whitlock.;Michael A Pulsipher.;Stephen P Hunger.;Mignon L Loh.
来源: JAMA. 2021年325卷9期833-842页
Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) or late relapse with residual disease after reinduction chemotherapy (intermediate risk). Blinatumomab, a bispecific CD3 to CD19 T cell-engaging antibody construct, is efficacious in relapsed/refractory B-ALL and has a favorable toxicity profile.
8232. Association Between COVID-19 Lockdown Measures and Emergency Department Visits for Violence-Related Injuries in Cardiff, Wales.
作者: Jonathan P Shepherd.;Simon C Moore.;Abigail Long.;Laura M Mercer Kollar.;Steven A Sumner.
来源: JAMA. 2021年325卷9期885-887页
This study investigates emergency department visits for violence-related injuries occurring at home and outside the home in Cardiff, Wales, before and after COVID-19 lockdown measures were instituted in March 2020.
8240. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
作者: Saman Saadat.;Zahra Rikhtegaran Tehrani.;James Logue.;Michelle Newman.;Matthew B Frieman.;Anthony D Harris.;Mohammad M Sajadi.
来源: JAMA. 2021年325卷14期1467-1469页
This study compares titers of binding and neutralizing antibodies after a single mRNA coronavirus vaccine dose in health care workers previously infected with SARS-CoV-2.
|